Timing is everything—monitoring drug patent expirations, assessing the regulatory landscape, and identifying competitive threats will define who wins and who falls behind.

This report breaks down:

• Top 5 blockbuster drugs losing patent protection in the next 5 years
• ~500 drug exclusivities expiring in 2026
• Generic Manufacturers, including ZYDUS PHARMA, ALEMBIC PHARMA, AUROBINDO PHARMA, DR REDDY’S, and more leading the market entry
• 150 drugs whose patents are listed on Orange Book are facing Litigation
• Ozempic, with $13.9B Annual Revenue, losing primary patent protection in 2026. Additional patents extend to 2033, meaning early entrants may face legal pushback.
• Brilinta, with $1.69B Annual Revenue, has a 2030 patent expiry, but Dr. Reddy’s secured an ANDA approval in October 2024.

Drugs like Ozempic ($13.9B), Abilify Maintena ($6.68B), Symbicort ($2.7B), Cabometyx ($1.6B), and Brilinta ($1.69B) will soon face their first generic competitors. The question isn’t if you should prepare—it’s how fast you can act before competitors do.

Download the report to stay ahead of these drug patent expirations.

Don’t Miss The Early Signs. Position Yourself for the Next Big Generic Launches.

Block Buster Drugs Patent Expirations

Some patent cliffs will be direct opportunities—high demand, clear approval pathways. Others will be battlegrounds, where exclusivity extensions, regulatory hurdles, or aggressive settlements dictate who enters and when.

Find key expiring patents and market opportunities transforming the generics industry. Download the report to position yourself ahead of these expirations.